Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Toll-like receptors as targets for allergen immunotherapy

Toll-like receptors as targets for allergen immunotherapy Downloaded from http://journals.lww.com/co-allergy by BhDMf5ePHKbH4TTImqenVA5KvPVPZ0P5BEgU+IUTEfzO/GUWifn2IfwcEVVH9SSn on 06/03/2020 REVIEW URRENT Toll-like receptors as targets for allergen PINION immunotherapy a b,c,d Zahra Aryan and Nima Rezaei Purpose of review Toll-like receptors (TLRs) are novel and promising targets for allergen immunotherapy. Bench studies suggest that TLR agonists reduce Th2 responses and ameliorate airway hyper-responsiveness. In addition, clinical trials are at initial phases to evaluate the safety and efficacy of TLR agonists for the allergen immunotherapy of patients with allergic rhinitis and asthma. Recent findings To date, two allergy vaccine-containing TLR agonists have been investigated in clinical trials; Pollinex Quattro and AIC. The former contains monophosphoryl lipid, a TLR4 agonist and the latter contains, CpG motifs activating the TLR9 cascade. Preseasonal subcutaneous injection of both of these allergy vaccines has been safe and efficacious in control of nasal symptoms of patients with allergic rhinitis. CRX-675 (a TLR4 agonist), AZD8848 (a TLR7 agonist), VTX-1463 (a TLR8 agonist) and 1018 ISS and QbG10 (TLR9 agonists) are currently in clinical development for allergic rhinitis and asthma. Summary TLR agonists herald promising results for allergen immunotherapy of patients with allergic rhinitis and asthma. Future research should be directed at utilizing these agents for immunotherapy of food allergy http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Current Opinion in Allergy & Clinical Immunology Wolters Kluwer Health

Toll-like receptors as targets for allergen immunotherapy

Download PDF
7 pages

Loading next page...
 
/lp/wolters-kluwer-health/toll-like-receptors-as-targets-for-allergen-immunotherapy-W4jBIid7uJ

References (63)

Publisher
Wolters Kluwer Health
ISSN
1528-4050
eISSN
1473-6322
DOI
10.1097/ACI.0000000000000212
Publisher site
See Article on Publisher Site

Abstract

Downloaded from http://journals.lww.com/co-allergy by BhDMf5ePHKbH4TTImqenVA5KvPVPZ0P5BEgU+IUTEfzO/GUWifn2IfwcEVVH9SSn on 06/03/2020 REVIEW URRENT Toll-like receptors as targets for allergen PINION immunotherapy a b,c,d Zahra Aryan and Nima Rezaei Purpose of review Toll-like receptors (TLRs) are novel and promising targets for allergen immunotherapy. Bench studies suggest that TLR agonists reduce Th2 responses and ameliorate airway hyper-responsiveness. In addition, clinical trials are at initial phases to evaluate the safety and efficacy of TLR agonists for the allergen immunotherapy of patients with allergic rhinitis and asthma. Recent findings To date, two allergy vaccine-containing TLR agonists have been investigated in clinical trials; Pollinex Quattro and AIC. The former contains monophosphoryl lipid, a TLR4 agonist and the latter contains, CpG motifs activating the TLR9 cascade. Preseasonal subcutaneous injection of both of these allergy vaccines has been safe and efficacious in control of nasal symptoms of patients with allergic rhinitis. CRX-675 (a TLR4 agonist), AZD8848 (a TLR7 agonist), VTX-1463 (a TLR8 agonist) and 1018 ISS and QbG10 (TLR9 agonists) are currently in clinical development for allergic rhinitis and asthma. Summary TLR agonists herald promising results for allergen immunotherapy of patients with allergic rhinitis and asthma. Future research should be directed at utilizing these agents for immunotherapy of food allergy

Journal

Current Opinion in Allergy & Clinical Immunology – Wolters Kluwer Health

Published: Dec 1, 2015

There are no references for this article.